Pharmaceutical companies face a significant shift in market access requirements as European regulators prepare to implement the Joint Clinical Assessment (JCA) framework for rare disease therapies starting in 2028. According to Steve Mather, Global Practice Lead of Strategy and Insight at Lumanity, this transition necessitates a fundamental change in how manufacturers approach evidence generation and long-term planning. Organizations that move toward integrated evidence strategies and establish robust governance years before launch are increasingly viewed as better positioned to secure patient access in a complex, evolving regulatory environment.
The upcoming implementation of the European Union’s Health Technology Assessment (HTA) Regulation represents a move toward centralized clinical evaluation of health technologies. While the regulation aims to harmonize the clinical assessment process across member states, it imposes new demands on pharmaceutical firms to align their research and development timelines with these centralized requirements. Experts note that the complexity of navigating country-specific care pathways remains a hurdle, even as the clinical component of assessments becomes more unified.
Strategic Planning for the 2028 Joint Clinical Assessment Deadline
The introduction of the JCA is part of a broader regulatory update intended to streamline how new medicines are evaluated for clinical effectiveness across the European Union. Under the EU Regulation 2021/2282, the joint clinical assessment process will be phased in, with advanced therapy medicinal products and oncology drugs being among the first to undergo this new procedure. For rare disease assets, this shift requires companies to look beyond traditional clinical trial endpoints.
Planning for these assessments requires organizations to identify appropriate comparators early in the development cycle. Because rare disease clinical trials often involve small patient populations, generating sufficient data to satisfy both the European Medicines Agency (EMA) and national HTA bodies can be challenging. According to industry analysis, companies that integrate real-world evidence (RWE) into their submission packages are more likely to address gaps left by limited head-to-head trial data. Governance structures that facilitate cross-functional collaboration between clinical, regulatory, and market access teams are now essential to meet these rigorous standards.
Learn more about the evolving landscape of drug commercialization through the Lumanity commercialization podcast series, which examines the intersection of policy and strategy.
Policy Convergence and Global Market Access Challenges
The pressure on pharmaceutical market access is not limited to Europe. Global firms are simultaneously managing the impact of the U.S. Inflation Reduction Act (IRA) and various international pricing reforms. The IRA, signed into law in August 2022, introduced significant changes to Medicare drug pricing, including the negotiation of prices for certain high-spend drugs, as detailed by the Centers for Medicare & Medicaid Services.
These policy shifts, including the consideration of Most-Favored-Nation (MFN) pricing models in various jurisdictions, create a high-stakes environment for global product launches. The cumulative effect of these regulations is a demand for earlier and more precise evidence generation. Companies that anticipate these cross-border policy impacts can better align their global pricing and reimbursement strategies. The central challenge for current leadership is balancing the need for rapid innovation in rare diseases with the increasing demand for transparent, evidence-based value demonstrations.
The Role of Real-World Evidence in Rare Disease Development
As the regulatory landscape matures, the reliance on real-world evidence is expected to grow, particularly for orphan drugs where randomized controlled trials may be difficult to execute. Regulatory bodies such as the EMA have published guidelines on the use of real-world data to support regulatory decision-making, emphasizing the need for high-quality, transparent data collection.
For many manufacturers, the future of market access rests on the ability to demonstrate value in the patient’s actual treatment environment. This involves:
- Early engagement with HTA bodies to define relevant clinical endpoints.
- Developing patient-reported outcome measures that reflect the burden of disease.
- Creating registries or using natural history studies to provide context for clinical trial results.
- Ensuring data integrity to meet the scrutiny of centralized assessment processes.
As the 2028 deadline approaches, pharmaceutical firms are expected to shift their internal resources toward earlier evidence planning. The ability to communicate the clinical value of rare disease treatments within the constraints of new, more rigid assessment frameworks will likely determine which therapies reach patients across diverse European markets.
Readers interested in further insights on this topic can follow Steve Mather on LinkedIn for professional updates and industry commentary regarding the future of pharmaceutical strategy.
The next major checkpoint for European stakeholders involves the continued rollout of the EU HTA Regulation’s procedural rules, with ongoing updates provided via the European Commission’s public health portal. We welcome your thoughts on how these policy changes will impact patient access to rare disease treatments in the coming years.